The cochairs of the AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers—Andrew Futreal, PhD, FAACR,...
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting...
Amid disruption in Ukraine, international partnerships are preserving oncology progress—and building the foundation for long-term recovery.
An AACR grant to study menin's structure gave researchers the 3D map they needed to produce new treatments for...
At the AACR Annual Meeting 2026, National Cancer Institute Director Anthony Letai offered insights into what NCI considers to...
An AACR Patient Advocate Forum assembled a panel of experts to discuss how AI tools can help advance cancer...
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.
Patient advocates from the AACR Scientist↔Survivor Program shared their research on cancer during the AACR Annual Meeting 2026.
A recap of the last day of the AACR Annual Meeting 2026, including plenaries on innovative treatment modalities and...
Injecting immunotherapy directly into precancerous oral lesions may be an effective way to prevent progression to cancer without surgery.